These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 28688124)
41. Chemoradiation in elderly patients with head and neck cancers: a single institution experience. Kataria T; Gupta D; Bisht SS; Goyal S; Basu T; Srivastava A; Abhishek A; Govardhan HB; Sharma K; Kumar V Am J Otolaryngol; 2015; 36(2):117-21. PubMed ID: 25442075 [TBL] [Abstract][Full Text] [Related]
42. Pretreatment performance status and nutrition are associated with early mortality of locally advanced head and neck cancer patients undergoing concurrent chemoradiation. Chang PH; Yeh KY; Huang JS; Lai CH; Wu TH; Lan YJ; Tsai JC; Chen EY; Yang SW; Wang CH Eur Arch Otorhinolaryngol; 2013 May; 270(6):1909-15. PubMed ID: 23188165 [TBL] [Abstract][Full Text] [Related]
43. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes. Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058 [TBL] [Abstract][Full Text] [Related]
44. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design. Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549 [TBL] [Abstract][Full Text] [Related]
45. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis. Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462 [TBL] [Abstract][Full Text] [Related]
46. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Tanvetyanon T; Padhya T; McCaffrey J; Kish JA; Deconti RC; Trotti A; Rao NG Head Neck; 2015 Jun; 37(6):840-5. PubMed ID: 24623654 [TBL] [Abstract][Full Text] [Related]
47. Concurrent Radiotherapy With Cetuximab or Platinum-based Chemotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck. Lu SM; Lien WW Am J Clin Oncol; 2018 Jan; 41(1):95-99. PubMed ID: 26353121 [TBL] [Abstract][Full Text] [Related]
48. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. Lee YJ; Lee CG; Cho BC; Kim GE; Choi HJ; Choi EC; Sohn JH; Kim JH Head Neck; 2010 Feb; 32(2):235-43. PubMed ID: 19572288 [TBL] [Abstract][Full Text] [Related]
49. Adjuvant Chemoradiation After Surgical Resection in Elderly Patients With High-Risk Squamous Cell Carcinoma of the Head and Neck: A National Cancer Database Analysis. Woody NM; Ward MC; Koyfman SA; Reddy CA; Geiger J; Joshi N; Burkey B; Scharpf J; Lamarre E; Prendes B; Adelstein DJ Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):784-792. PubMed ID: 28602410 [TBL] [Abstract][Full Text] [Related]
50. High serum carbonic anhydrase IX predicts shorter survival in head and neck cancer. Rosenberg V; Pastorekova S; Zatovicova M; Vidlickova I; Jelenska L; Slezak P Bratisl Lek Listy; 2016; 117(4):201-4. PubMed ID: 27075382 [TBL] [Abstract][Full Text] [Related]
51. A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy. Soltys SG; Choi CY; Fee WE; Pinto HA; Le QT Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):994-9. PubMed ID: 22137026 [TBL] [Abstract][Full Text] [Related]
52. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662 [TBL] [Abstract][Full Text] [Related]
53. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504 [TBL] [Abstract][Full Text] [Related]
54. Treatment outcome for head and neck squamous cell carcinoma in a developing country: University Malaya Medical Centre, Malaysia from 2003-2010. Wong YF; Yusof MM; Wan Ishak WZ; Alip A; Phua VC Asian Pac J Cancer Prev; 2015; 16(7):2903-8. PubMed ID: 25854381 [TBL] [Abstract][Full Text] [Related]
55. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959 [TBL] [Abstract][Full Text] [Related]
56. Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer. Zumsteg ZS; Kim S; David JM; Yoshida EJ; Tighiouart M; Shiao SL; Scher K; Mita A; Sherman EJ; Lee NY; Ho AS Cancer; 2017 May; 123(9):1555-1565. PubMed ID: 28001302 [TBL] [Abstract][Full Text] [Related]
57. Prognostic value of PET/CT with (18)F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy. Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Obata T; Tanimoto K; Harada R; Uno T; Fujibayashi Y Ann Nucl Med; 2016 Apr; 30(3):217-24. PubMed ID: 26662072 [TBL] [Abstract][Full Text] [Related]
58. Risk Factors Associated with Disease Recurrence in Patients with Stage III/IV Squamous Cell Carcinoma of the Oral Cavity Treated with Surgery and Postoperative Radiotherapy. Noble AR; Greskovich JF; Han J; Reddy CA; Nwizu TI; Khan MF; Scharpf J; Adelstein DJ; Burkey BB; Koyfman SA Anticancer Res; 2016 Feb; 36(2):785-92. PubMed ID: 26851040 [TBL] [Abstract][Full Text] [Related]
59. Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer. Trifiletti DM; Smith A; Mitra N; Grover S; Lukens JN; Cohen RB; Read P; Mendenhall WM; Lin A; Swisher-McClure S J Clin Oncol; 2017 May; 35(14):1550-1560. PubMed ID: 28475848 [TBL] [Abstract][Full Text] [Related]
60. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan. Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]